E2F7 is a transcription factor that participates in various processes such as cell cycle regulation and DNA damage response by mediating transcriptional repression of target genes involved in G1/S regulation as well as in DNA replication and repair.
| Inventor | Institute |
|---|---|
| Ana Maria Zubiaga ; Iraia Garcia Santisteban | University of the Basque Country (EHU) |
| SKU: | 156469 |
|---|---|
| Product description: | E2F7 is a transcription factor that participates in various processes such as cell cycle regulation and DNA damage response by mediating transcriptional repression of target genes involved in G1/S regulation as well as in DNA replication and repair. |
| Alternate name: | U-2 OS |
| Conditional: | No |
| Production details: | E2F7 knockout cells were generated using the CRISPR/Cas9 system. A CRISPR guide RNA (gRNA) targeting the first coding exon of E2F7 was designed using Benchling, and cloned into the BbsI site of pX330 (42230, Addgene). U2OS cells were co-transfected with this plasmid, together with a plasmid containing a gRNA to the zebrafish TIA gene (5 -GGTATGTCGGGAACCTCTCC3 ) and a P2A-puromycin resistance cassette flanked by two TIA target sites. Co-transfection results in excision of the cassette and subs… |
| Additional notes: | CRISPR edited U2OS cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provid… |
| Parental cell line: | U2OS |
| Disease: | Cancer |
| Cat. #: | 156469 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Research Fields: | Cancer; Cell biology |
| Organism: | Human |
| Tissue: | Bone |
| Model: | Knock-Out |
| Growth properties: | Increased G2/M checkpoint recovery competence and improved viability upon treatment with compounds that affect replication fork progression (cisplatin, mitomycin C, olaparib). |
| Cancer Types In Detail: | Osteosarcoma cell line |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) |
| Recommended controls: | Parental U2OS cells, puromycin sensitive |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Mitxelena et al. 2018. Nucleic Acids Res. 46(9):4546-4559. PMID: 29590434. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.